Background To compare the efficacy of chemotherapy (C) combined with bevacizumab (Bev) versus Bev alone in recurrent, heavily pretreated epithelial ovarian cancer (EOC). Methods A multicenter analysis of patients treated from 2004 to 2011 was performed. Demographic, treatment, response, and adverse event information were obtained. Progression-free (PFS) and overall survival (OS) were analyzed. Results Of 277 patients (median age: 58 years), the majority had Stage III and IV (86%) disease, and 72% had serous histology. 244 (88%) were treated with C + Bev and 33 (12%) with Bev. Corresponding median progression-free survival (PFS) was 8.7 and 6.7 months, and median overall survival (OS) was 14.3 and 10.5 months, respectively. The chemotherapeutic agents combined with Bev and the median OS include: pegylated liposomal doxorubicin (n = 19, OS of 20.4 months), taxanes (n = 55, OS of 20.2 months), gemcitabine (n = 106, OS of 14.1 months), topotecan (n = 43, OS of 13 months), and cyclophosphamide (n = 21, OS of 13 months). There was no significant difference in toxicities between the C + Bev vs. Bev alone group. Conclusion This retrospective analysis supports that combination chemotherapy and bevacizumab prolongs PFS and OS compared with bevacizumab alone.
- Liposomal doxorubicin, taxanes
- Recurrent epithelial ovarian cancer